Stockreport

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... [Yahoo! Finance]

Lantern Pharma Inc.  (LTRN) 
PDF R&D Expenses: Approximately $3.7 million for Q3 2024, up from $2.2 million for Q3 2023. General and Administrative Expenses: Approximately $1.5 million for Q3 2024, u [Read more]